| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ad2149723c082aa595d0d768bf1df2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b862d9a395dc549e3557ddb96dff8af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcfd400f6623894732f69daf1747132e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate |
2009-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86eb5bfe29536452ec7affde9d6aa7eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a6bc06a4c5b35681f4745ae869edff4 |
| publicationDate |
2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009134723-A1 |
| titleOfInvention |
Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer |
| abstract |
The subject matter of the instant invention is pertinent to the field of cancer treatment. In particular, the instant invention is relevant to the treatment and/or prevention of breast cancer in a patient. Compositions for practicing the methods, comprising selective progesterone receptor modulators, which function as progesterone agonists in the uterus and as progesterone antagonists in the breast tissue and exhibit only low affinity for glucocorticoid and estrogen receptors, are also disclosed. Embodiments of the instant invention also disclose methods for preventing the development of breast cancer in patients undergoing hormone replacement therapy or estrogen therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106414475-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106414475-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2997628-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-029643-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MD-4546-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011157443-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591338-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014072647-A1 |
| priorityDate |
2008-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |